Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cilansetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.61 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.61 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.61 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.61 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.61 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.61 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.61 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.61 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.61 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.61 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.61 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilansetron SCHEMBL29883543 | 1.00 | CYP3A4 (0.61) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Cilansetron SCHEMBL678512 | 1.00 | CYP3A4 (0.61) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Cilansetron SCHEMBL7427797 | 1.00 | CYP3A4 (0.61) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Cilansetron SCHEMBL29019018 | 0.99 | CYP3A4 (0.60) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Cilansetron SCHEMBL29883205 | 0.99 | CYP3A4 (0.60) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Cilansetron SCHEMBL7433386 | 0.99 | CYP3A4 (0.60) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Cilansetron SCHEMBL5764110 | 0.99 | CYP3A4 (0.60) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Cilansetron SCHEMBL3157229 | 0.99 | CYP3A4 (0.60) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Cilansetron SCHEMBL3452925 | 0.98 | CYP3A4 (0.59) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL21043399 | 0.88 | CYP3A4 (0.47) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2243 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-119925269-A | Sivelesta sodium suspension, freeze-dried powder, atomized inhalant and preparation method thereof | 暨南大学 | 2025-05-06 | — | — | CN | claimed |
| US-12257282-B2 | Mixtures and formulations | CAMARUS AB (SE) | 2025-03-25 | — | — | US | claimed |
| CN-119185259-A | Sivelesta sodium inhalation composition, medicine assembly and application thereof | 盈科瑞（横琴）药物研究院有限公司 | 2024-12-27 | — | — | CN | claimed |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| CN-117982414-B | Sivelesta sodium nanocrystalline, dry powder and inhalation powder fog agent thereof and preparation method thereof | 暨南大学 | 2024-07-02 | — | — | CN | claimed |
| CN-117982414-A | Sivelesta sodium nanocrystalline, dry powder and inhalation powder fog agent thereof and preparation method thereof | 暨南大学 | 2024-05-07 | — | — | CN | claimed |
| CN-115144513-B | Method for determining concentration of cilveliroxostat in organism | 上海谱锐赛思生物技术有限公司 | 2024-02-06 | — | — | CN | claimed |
| US-20240009173-A1 | Use of 5-HT3-Targeting Drugs for Treatment of Acute Kidney Injury | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-01-11 | — | — | US | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| WO-2002007713-A2 | MEDICAMENTS CONTAINING CILANSETRON FOR TREATING NON-OBSTIPATED MALE IBS PATIENTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2002-01-31 | — | — | WO | claimed |
| WO-2001095903-A1 | 5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF DISORDERS INVOLVING AIRWAY CONSTRICTION | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| US-20010044450-A1 | Medicaments | SEBELA INTERNATIONAL LIMITED (BM) | 2001-11-22 | — | — | US | claimed |
| US-6284770-B1 | ADMINISTERING SEROTONINE RECEPTOR ANTAGONIST | GLAXO WELLCOME INC. | 2001-09-04 | — | — | US | claimed |
| CN-1281357-A | Medicaments | GLAXO GROUP LTD (GB) | 2001-01-24 | — | — | CN | claimed |
| WO-2000076500-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-12-21 | — | — | WO | claimed |
| EP-1021174-A2 | MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 2000-07-26 | — | — | EP | claimed |
| US-5977127-A | WATER SOLUBLE STABILIZING ACID ADDITIVE WHOSE PKS VALUE FALLS WITHIN A GIVEN RANGE, SUCH AS CITRIC ACID OR ABSORBIC ACID IN SPECIFIC MOLAR RATIO | SOLVAY PHARMACEUTICALS GMBH (DE) | 1999-11-02 | — | — | US | claimed |
| WO-1999017755-A2 | MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 1999-04-15 | — | — | WO | claimed |
| EP-0895782-A2 | Pharmaceutical compositions of Cilansetron stabilized against racemisation | Solvay Pharmaceuticals GmbH (DE) | 1999-02-10 | — | — | EP | claimed |